Filing Details

Accession Number:
0001104659-21-134623
Form Type:
4
Zero Holdings:
No
Publication Time:
2021-11-04 21:00:33
Reporting Period:
2021-11-02
Accepted Time:
2021-11-04 21:00:33
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1689375 Entrada Therapeutics Inc. TRDA () DE
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1425738 Redmile Group, Llc One Letterman Drive
Building D, Suite D3-300
San Francisco CA 94129
No No Yes No
1650527 Jeremy Green C/O Redmile Group, Llc
One Letterman Drive, Building D #D3-300
San Francisco CA 94129
No No Yes No
1838746 Redmile Biopharma Investments Iii, L.p. C/O Redmile Group, Llc
One Letterman Drive, Building D # D3-300
San Francisco CA 94129
No No Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2021-11-02 954,420 $0.00 954,420 No 4 C Indirect See Footnote
Common Stock Acquisiton 2021-11-02 1,000,000 $20.00 1,954,420 No 4 P Indirect See Footnote
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 C Indirect See Footnote
No 4 P Indirect See Footnote
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Series B Convertible Preferred Stock Disposition 2021-11-02 954,420 $0.00 954,420 $0.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 No 4 C Indirect
Footnotes
  1. The Series B convertible preferred stock automatically converted into shares of the Issuer's common stock upon the closing of the Issuer's initial public offering for no consideration. The Series B convertible preferred stock had no expiration date.
  2. These securities are directly owned by certain private investment vehicles managed by Redmile Group, LLC ("Redmile"), including Redmile Biopharma Investments III, L.P., and may be deemed beneficially owned by Redmile as investment manager of such private investment vehicles. The reported securities may also be deemed beneficially owned by Jeremy Green as the principal of Redmile. Each of Redmile and Mr. Green (the "Managing Persons") disclaims beneficial ownership of the reported securities except to the extent of their pecuniary interest therein. This report shall not be deemed an admission that such Managing Persons are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.
  3. Reflects number of shares owned as of November 2, 2021.